Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Meyer, D S ^a,d   Koren, S ^a   Leroy, C ^a,b   Brinkhaus, H ^a   Muller U ^a   Klebba, I ^a,e   Muller M ^b   Cardiff, R D ^c   Bentires Alj, M ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC SUBUNIT ALPHA; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRANSGENE;

EID: 84885435958     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.38     Document Type: Article

References (30)

1. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: Variations on a theme. Oncogene 2008; 27: 5497-5510.
2. Manning BD, Cantley LC. AKT/PKB signaling: Navigating downstream. Cell 2007; 129: 1261-1274.
3. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3: 772-775.
4. Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N et al. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res 2009; 69: 7357-7365.
5. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clinical cancer research: An official journal of the American Association for Cancer Research 2005; 11: 2875-2878.
6. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
7. Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005; 7: R609-R616.
8. Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z et al. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol 2012; 40: 639-644.
9. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5: 921-929.
10. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006; 103: 1475-1479.
11. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005; 65: 10992-11000.
12. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 2005; 102: 18443-18448.
13. Koren S, Bentires-Alj M. Mouse models of PIK3CA mutations: One mutation initiates heterogeneous mammary tumors. FEBS J 2013; 280: 2758-2765.
14. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008; 105: 2652-2657.
15. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007; 13: 6064-6069.
16. Miller TW. Initiating breast cancer by PIK3CA mutation. Breast Cancer Res 2012; 14: 301.
17. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65: 2554-2559.
18. Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 2010; 70: 5674-5678.
19. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009; 15: 5049-5059.
20. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY. PIK3CA exon mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 2008; 15: 1064-1069. Cancer Genome Atlas Network.
21. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
22. Meyer DS, Brinkhaus H, Muller U, Muller M, Cardiff RD, Bentires-Alj M. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res 2011; 71: 4344-4351.
23. Adams JR, Xu K, Liu JC, Agamez NM, Loch AJ, Wong RG et al. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res 2011; 71: 2706-2717.
24. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 2011; 17: 1116-1120.
25. Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R et al. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERalpha-positive tumors. PLoS One 2012; 7: E36924.
26. Tchorz JS, Kinter J, Muller M, Tornillo L, Heim MH, Bettler B. Notch2 signaling promotes biliary epithelial cell fate specification and tubulogenesis during bile duct development in mice. Hepatology 2009; 50: 871-879.
27. Wintermantel TM, Mayer AK, Schutz G, Greiner EF. Targeting mammary epithelial cells using a bacterial artificial chromosome. Genesis 2002; 33: 125-130.
28. Boulanger CA, Wagner KU, Smith GH. Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression. Oncogene 2005; 24: 552-560.
29. Booth BW, Boulanger CA, Smith GH. Alveolar progenitor cells develop in mouse mammary glands independent of pregnancy and lactation. J Cell Physiol 2007; 212: 729-736.
30. Bruno RD, Smith GH. Functional characterization of stem cell activity in the mouse mammary gland. Stem Cell Rev 2011; 7: 238-247.